Potential treatment for myasthenia gravis adapted from CAR-T therapy

Evidence from a small-scale clinical trial suggests that a variation of the advanced blood cancer immunotherapy known as CAR-T could be adapted to treat myasthenia gravis. The modified CAR-T therapy, known as Descartes-08, offers the potential for a longer-lasting reduction in myasthenia gravis symptoms and was well tolerated without significant adverse effects.